Acute effects while under the influence include euphoria, increased appetite, anxiety, short-term memory loss, and circulation effects which may increase risks of heart attacks. The evidence of long-term effects on memory is preliminary and hindered by confounding factors. Concerns have been raised about the potential for long-term cannabis consumption to increase risk for schizophrenia, bipolar disorders, and major depression, but the ultimate conclusions on these factors are disputed.
Cannabis smoking is the most common method of consumption, either by manually rolling a mixture of tobacco and cannabis into a cigarette (called a "joint" or "spliff"), or by directly burning properly sifted cannabis, often at far lower temperatures, in a pipe or bong. As cigarette smoking is credited with causing most of the 5.4 million premature deaths per year worldwide attributed to tobacco , similarly the practice of "rolling a joint" may cause pathologies in "heavy users" of cannabis which are attributed to the cannabis. At least one source has suggested that the practice of mixing tobacco with cannabis can lead to nicotine dependence.
Vaporization is a much less harmful alternative to smoking and seems to be well suited for medical use. Rather than burning the herb, which produces numerous harmful by-products, a vaporizer heats the material, ideally to 180°C (356°F), so that the active compounds contained in the cannabis boil off, converting them into a gas to be inhaled. This gas is not smoke from combustion, but instead a vapor which has the appearance of smoke. The vapor ideally contains virtually zero particulate matter (tar) and reduced noxious gases such as carbon monoxide.
Studies have shown that vaporizers can dramatically reduce or even eliminate the release of irritants and toxic compounds.
The onset of effects from the inhalation of cannabis vapor is very rapid similar to smoking. In comparison, the effects of oral consumption of cannabis may take about two hours.
This product, developed in China, has a rechargeable battery and a heating element which vaporizes (in most brands) liquid nicotine out of an insertable cartridge. If THC were loaded into the cartridge instead of nicotine, the e-cigarette would provide cannabis users many advantages of a vaporizer at lower initial cost.
The most prevalent group of psychoactive substances in cannabis is cannabinoids including delta-9-tetrahydrocannabinol (commonly called Δ9-THC, or simply THC). In the past two decades, the average content of THC in marijuana sold in North America has increased from about 1% to 3-4% or more. Some species, that undergone careful selection and growing techniques can even yield a product with as much as 29% THC. Another psychoactive cannabinoid present in Cannabis sativa is Tetrahydrocannabivarin (THCV), but it is only found in small amounts.
In addition, there are also similar compounds contained in cannabis that do not exhibit any psychoactive response but are obligatory for functionality: cannabidiol (CBD), an isomer of THC; cannabinol (CBN), an oxidation product of THC; cannabivarin (CBV), an analog of CBN with a different sidechain, cannabidivarin (CBDV), an analog of CBD with a different side chain, and cannabinolic acid. How these other compounds interact with THC is not fully understood. Some clinical studies have proposed that CBD acts as a balancing force to regulate the strength of the psychoactive agent THC. Anecdotal and inconclusive reports claim that marijuana with relatively high ratios of THC:CBD is less likely to induce anxiety than marijuana with low THC:CBD ratios. CBD is also believed to regulate the body’s metabolism of THC by inactivating cytochrome P450, an important class of enzymes that metabolize drugs. Experiments in which mice were treated with CBD followed by THC showed that CBD treatment was associated with a substantial increase in brain concentrations of THC and its major metabolites, most likely because it decreased the rate of clearance of THC from the body. Cannabis cofactor compounds have also been linked to lowering body temperature, modulating immune functioning, and cell protection. The essential oil of cannabis contains many fragrant terpenoids which may synergize with the cannabinoids to produce their unique effects. THC is converted rapidly to 11-hydroxy-THC, which is also pharmacologically active, so the drug effect outlasts measurable THC levels in blood.
THC and cannabidiol are also neuroprotective antioxidants. Research in rats has indicated that THC prevented hydroperoxide-induced oxidative damage as well as or better than other antioxidants in a chemical (Fenton reaction) system and neuronal cultures. Cannabidiol was significantly more protective than either α-tocopherol (vitamin E) or ascorbate (vitamin C).
In 1990, the discovery of cannabinoid receptors located throughout the brain and body, along with endogenous cannabinoid neurotransmitters like anandamide (a lipid material derived ligand from arachidonic acid), suggested that the use of cannabis affects the brain in the same manner as a naturally occurring brain chemical. Cannabinoids usually contain a 1,1'-di-methyl-pyrane ring, a variedly derivatized aromatic ring and a variedly unsaturated cyclohexyl ring and their immediate chemical precursors, constituting a family of about 60 bi-cyclic and tri-cyclic compounds. Like most other neurological processes, the effects of cannabis on the brain follow the standard protocol of signal transduction, the electrochemical system of sending signals through neurons for a biological response. It is now understood that cannabinoid receptors appear in similar forms in most vertebrates and invertebrates and have a long evolutionary history of 500 million years. Cannabinoid receptors decrease adenylyl cyclase activity, inhibit calcium N channels, and disinhibit K+A channels. There are two types of cannabinoid receptors (CB1 and CB2).
The CB1 receptor is found primarily in the brain and mediates the psychological effects of THC. The CB2 receptor is most abundantly found on cells of the immune system. Cannabinoids act as immunomodulators at CB2 receptors, meaning they increase some immune responses and decrease others. For example, nonpsychotropic cannabinoids can be used as a very effective anti-inflammatory. The affinity of cannabinoids to bind to either receptor is about the same, with only a slight increase observed with the plant-derived compound CBD binding to CB2 receptors more frequently. Cannabinoids likely have a role in the brain’s control of movement and memory, as well as natural pain modulation. It is clear that cannabinoids can affect pain transmission and, specifically, that cannabinoids interact with the brain's endogenous opioid system and may affect dopamine transmission. This is an important physiological pathway for the medical treatment of pain.
The cannabinoid receptor is a typical member of the largest known family of receptors called a G protein-coupled receptor. A signature of this type of receptor is the distinct pattern of how the receptor molecule spans the cell membrane seven times. The location of cannabinoid receptors exists on the cell membrane, and both outside (extracellularly) and inside (intracellularly) the cell membrane. CB1 receptors, the bigger of the two, are extraordinarily abundant in the brain: 10 times more plentiful than μ-opioid receptors, the receptors responsible for the effects of morphine. CB2 receptors are structurally different (the homology between the two subtypes of receptors is 44%), found only on cells of the immune system, and seems to function similarly to its CB1 counterpart. CB2 receptors are most commonly prevalent on B-cells, natural killer cells, and monocytes, but can also be found on polymorphonuclear neurtrophil cells, T8 cells, and T4 cells. In the tonsils the CB2 receptors appear to be restricted to B-lymphocyte-enriched areas.
THC and endogenous anandamide additionally interact with glycine receptors.
Cannabis also contains a related class of compound: the cannaflavins. These compounds have been suggested to contribute certain effects of cannabis, such as analgesia and anti-inflammatory properties, and are considerably more effective than aspirin. Cannaflavins usually contain a 1,4-pyrone ring fused to a variedly derivatized aromatic ring and linked to a 2nd variedly derivatized aromatic ring and include for example the non-psychoactive cannflavin A and B.
Cannabis also produces many subjective effects, such as greater enjoyment of food's taste and aroma and an enhanced enjoyment of music and comedy. At higher doses, cannabis can cause marked distortions in time and space perception, altered body image, auditory and/or visual illusions, ataxia from selective impairment of polysynaptic reflexes, and depersonalization to all of which carbon monoxide toxicity (in the cigarette paper format) contributes.
A study of ten healthy, robust, male volunteers who resided in a residential research facility sought to examine both acute and residual subjective, physiologic, and performance effects of smoking marijuana cigarettes. On three separate days, subjects smoked one NIDA marijuana cigarette containing either 0%, 1.8%, or 3.6% THC, documenting subjective, physiologic, and performance measures prior to smoking, five times following smoking on that day, and three times on the following morning. Subjects reported robust subjective effects following both active doses of marijuana, which returned to baseline levels within 3.5 hours. Heart rate increased and the puplilary light reflex decreased following active dose administration with return to baseline on that day. Additionally, marijuana smoking acutely produced decrements in smooth pursuit eye tracking. Although robust acute effects of marijuana were found on subjective and physiological measures, no effects were evident the day following administration, indicating that the residual effects of smoking a single marijuana cigarette are minimal.
Another study showed that consumption of 15 mg of Delta(9)-THC resulted in no learning whatsoever occurring over a three-trial selective reminding task after two hours. In several tasks, delta(9)-THC increased both speed and error rates, reflecting “riskier” speed–accuracy trade-offs.
The areas of the brain where cannabinoid receptors are most prevalently located are consistent with the behavioral effects produced by cannabinoids. Brain regions in which cannabinoid receptors are very abundant are the basal ganglia, associated with movement control; the cerebellum, associated with body movement coordination; the hippocampus, associated with learning, memory, and stress control; the cerebral cortex, associated with higher cognitive functions; and the nucleus accumbens, regarded as the reward center of the brain. Other regions where cannabinoid receptors are moderately concentrated are the hypothalamus, which regulates homeostatic functions; the amygdala, associated with emotional responses and fears; the spinal cord, associated with peripheral sensations like pain; the brain stem, associated with sleep, arousal, and motor control; and the nucleus of the solitary tract, associated with visceral sensations like nausea and vomiting.
Most notably, the two areas of motor control and memory are where the effects of cannabis are directly and irrefutably evident. Cannabinoids, depending on the dose, inhibit the transmission of neural signals through the basal ganglia and cerebellum. At lower doses, cannabinoids seem to stimulate locomotion while greater doses inhibit it, most commonly manifested by lack of steadiness (body sway and hand steadiness) in motor tasks that require a lot of attention. Other brain regions, like the cortex, the cerebellum, and the neural pathway from cortex to striatum, are also involved in the control of movement and contain abundant cannabinoid receptors, indicating their possible involvement as well.
Experiments on animal and human tissue have shown the potential for the disruption of short-term memory, which is consistent with the abundance of CB1 receptors on the hippocampus, the region of the brain most closely associated with memory. Cannabinoids inhibit the release of several neurotransmitters in the hippocampus, like acetylcholine, norepinephrine, and glutamate, resulting in a major decrease in neuronal activity in that region. This decrease in activity resembles a "temporary hippocampal lesion." In the end, this procedure could lead to the blocking of cellular processes that are associated with memory formation. As the drug is metabolized, normal neurological activity is eventually restored.
In in-vitro experiments THC at extremely high concentrations, which could not be reached with commonly consumed doses, caused competitive inhibition of the AChE enzyme and inhibition of β-amyloid peptide aggregation, the cause of Alzheimer's disease. Compared to currently approved drugs prescribed for the treatment of Alzheimer's disease, THC is a considerably superior inhibitor of A aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease.
A 2001 study by the United Kingdom Transit Research Laboratory (TRL) specifically focuses on the effects of cannabis use on driving (see report here: ), and is one of the most recent and commonly quoted studies on the subject. The report summarizes current knowledge about the effects of cannabis on driving and accident risk based on a review of available literature published since 1994 and the effects of cannabis on laboratory based tasks.
The study identified young males, amongst whom cannabis consumption is frequent and increasing, and in whom alcohol consumption is also common, as a risk group for traffic accidents. This is due to driving inexperience and factors associated with youth relating to risk taking, delinquency and motivation. These demographic and psychosocial variables may relate to both drug use and accident risk, thereby presenting an artificial relationship between use of drugs and accident involvement.
The effects of cannabis on laboratory-based tasks show clear impairment with respect to tracking ability, attention, and other tasks depending on the dose administered. These effects however, are not as pronounced on real world tasks, like driving or simulator tasks. Both simulation and road trials generally find that driving behavior shortly after consumption of larger doses of cannabis results in:
Whereas these results indicate a 'change' from normal conditions, they do not necessarily reflect 'impairment' in terms of performance effectiveness, since few studies report increased accident risk. However, the results do suggest 'impairment' in terms of performance efficiency given that some of these behaviors may limit the available resources to cope with any additional, unexpected or high demand, events. Indeed, compensatory effort may be invoked to offset impairment in the driving task. Subjects under cannabis treatment may perceive that they are impaired and may strategically compensate, for example, by not overtaking, by slowing down and by focusing their attention when they know a response will be required. This compensatory effort may be one reason for the failure to implicate cannabis consumption as an accident risk factor, particularly at lower doses or with more than about one hour after consumption. According to the TRL study, the same compensatory behavior could also be an unconscious adaptation, similar to reduced driving speeds used by a sleepy driver.
Specifically, 4-12% of accident fatalities have detected levels of cannabis. However, most studies report that the majority of fatal cases with detected levels of cannabis are compounded by alcohol.
The study estimates 11 ng/ml THC as the equivalent dose to the legal limit of alcohol (0.08% BAC in the UK). Complicating this assessment is the fact that cannabis effects on driving fade after a short period of time, while some THC may be present in the body for weeks.
Similar conclusions have been reached by studies maintained by the federal governments of Australia, United Kingdom, New Zealand and the United States (see here for a list of studies). Those studies that have concluded that cannabis has a significant negative effect on driving ability generally involve the use of roadside sobriety tests as an indicator of reduced ability (for example, see this NIDA report). However, studies that employ this methodology show that a majority of subjects who tested positive for THC also tested positive for alcohol, already described as a limiting factor of validity.
According to the Merck Index, the LD50 (dosage lethal to 50% of rats tested) of Δ9-THC by inhalation is 42 mg/kg of body weight. That is the equivalent of a man weighing 75 kg (164.0625 lb) inhaling the THC found in 21 grams of extremely high-potency (15% THC) marijuana all in one sitting, assuming no THC is lost through smoke loss or absorption by the lungs. For oral consumption, the LD50 for male rats is 1270 mg/kg, and 730 mg/kg for females—equivalent to the THC in about a pound of 15% THC marijuana.
The ratio of cannabis material required to produce a fatal overdose to the amount required to saturate cannabinoid receptors and cause intoxication is 40,000:1 ; consumption of such a large dose is virtually impossible. There have been no reported deaths or permanent injuries sustained as a result of a marijuana overdose It is, for all practical purposes, impossible to overdose on marijuana, as the user would certainly either fall asleep or otherwise become incapacitated from the effects of the drug before being able to consume enough THC to be mortally toxic. According to a 2006 United Kingdom government report, using cannabis is much less dangerous than tobacco, prescription drugs, and alcohol in social harms, physical harm, and addiction. It was found in 2007 that while tobacco and cannabis smoke are quite similar, cannabis smoke contained higher amounts of ammonia, hydrogen cyanide, and nitrogen oxides, but lower levels of carcinogenic polycyclic aromatic hydrocarbons (PAHs).
A 2008 study by the National Institutes of Health suggested a link between heavy long-term marijuana smoking (138 joints per week over 6 years) and increased risk of heart attack or stroke.
Cannabis also has been shown to have a synergistic cytotoxic effect on lung cancer cell cultures in vitro with the food additive butylated hydroxyanisole (BHA) and possibly the related compound butylated hydroxytoluene (BHT). The study concluded, "Exposure to marijuana smoke in conjunction with BHA, a common food additive, may promote deleterious health effects in the lung." BHA & BHT are human-made fat preservatives, and are found in many packaged foods including: plastics in boxed Cereal, Jello, Slim Jims, and more.
Research has demonstrated that human sperm contains receptors which are stimulated by substances like THC and other cannabis-related chemicals. Tests have implied that smoking of marijuana could impact the sperm's functions, though this impact is unknown.
A study of the development of 59 Jamaican children was conducted with the children being monitored from child birth to age 5 years. One-half of the sample's mothers used marijuana during pregnancy; they were paired with non-using mothers who matched age, parity, and socioeconomic status. Testing was done at 1, 3, and 30 days of age with the Brazelton Neonatal Behavioral Assessment Scales, and at ages 4 and 5 years with the McCarthy Scales of Children's Abilities test. Data was also collected from the child's home environment and temperament, as well as standardized tests. The results over the entire research period showed no significant differences in development testing outcomes between using and non-using mothers. At 30 days of age, however, the children of marijuana-using mothers had higher scores on autonomic stability and reflexes. The absence of any differences between the exposed and non-exposed groups in the early neonatal period suggest that the better scores of exposed neonates at 1 month are traceable to the cultural positioning and social and economic characteristics of mothers using marijuana that select for the use of marijuana but also promote neonatal development.
Some studies have found that children of tobacco and marijuana-smoking mothers more frequently suffer from permanent cognitive deficits, concentration disorders, hyperactivity, and impaired social interactions than non-exposed children of the same age and social background. A recent study, with participation of scientists from Europe and the United States, has now identified that naturally occurring endocannabinoid molecules play a role in establishing how certain nerve cells connect to each other in the fetal brain. Another study examining cannabinoid receptor proteins (CBRs) expressed in brain cells of mice determined that endogenous endocannabinoids assist in directing brain cell directional development while in the womb. The researchers suggest that elevated blood THC levels due to cannabis consumption would affect brain development of human fetuses. In contrast, other studies in Jamaica have suggested that cannabis use by expectant mothers does not appear to cause birth defects or developmental delays in their newborn children.
Preliminary research, published in the April 2006 issue of the Journal of Consulting and Clinical Psychology, indicates that cannabis addiction can be offset by a combination of cognitive-behavioral therapy and motivational incentives. Participants in the study (previously diagnosed with marijuana dependence) received either vouchers as incentives to stay drug free, cognitive-behavioral therapy, or both over a 14-week period. At the end of 3 months, 43 percent of those who received both treatments were no longer using marijuana, compared with 40 percent of the voucher group, and 30 percent of the therapy group. At the end of a 12-month follow-up, 37 percent of those who got both treatments remained abstinent, compared with 17 percent of the voucher group, and 23 percent of the therapy group.
A 1998 French governmental report commissioned by Health Secretary of State Bernard Kouchner, and directed by Dr. Pierre-Bernard Roques, classed drugs according to addictiveness and neurotoxicity. It placed heroin, cocaine and alcohol in the most addictive and lethal categories; benzodiazepine, hallucinogens and tobacco in the medium category, and cannabis in the last category. The report stated that "Addiction to cannabis does not involve neurotoxicity such as it was defined in chapter 3 by neuroanatomical, neurochemical and behavioral criteria. Thus, former results suggesting anatomic changes in the brain of chronic cannabis users, measured by tomography, were not confirmed by the accurate modern neuro-imaging techniques. Moreover, morphological impairment of the hippocampus [which plays a part in memory and navigation] of rat after administration of very high doses of THC (Langfield et al., 1988) was not shown (Slikker et al., 1992)." Health Secretary Bernard Kouchner concluded that : "Scientific facts show that, for cannabis, no neurotoxicity is demonstrated, to the contrary of alcohol and cocaine.
A common interpretation of the correlation and theorized direction of the causality is the self-medication hypothesis, which is based on partially or fully attributing the correlation between psychiatric diseases and cannabis to the extensive substance abuse among sufferers of certain mental disorders, before diagnosis in many cases, which increases the likeliness of cannabis use among the mentally ill and the undiagnosed, thus accounting for correlation and debunking some claims of causality with the opposite direction. As much as 60% of the mentally ill are suspected to be substance abusers, and many seem to prefer cannabis and alcohol. Dr Stanley Zammit of Bristol and Cardiff universities (in the Daily express newspaper of the 27th of July 2007) reported "Even if cannabis did increase the risk of psychosis, most people using the drug would not get ill" But he added: "Nevertheless, we would still advise people to avoid or limit their use of this drug, especially if they start to develop any mental health symptoms or if they have relatives with psychotic illnesses." A 2007 study of studies published in the Lancet concluded that cannabis users are 40% more likely to be sufferers of a psychotic illness than non-users. In comparison, alcohol, as the only intoxicating drug with similar levels of popularity, has been linked to more than 65% of all suicides in a UK study, and linked to general psychiatric mental health problems including depression, anxiety, schizophrenia, psychosis, psychoneurosis, Post Traumatic Stress Disorder, physical brain damage and more. That is not to suggest that alcohol can cause schizophrenia, and if it were to cause temporary psychosis, it would be ameliorated after cessation of its consumption.
A large unselected, population-based study, published in British Journal of Psychiatry (2008), examined cannabis use and prodromal symptoms of psychosis at age 15–16 years and conclude that cannabis use is associated with prodromal symptoms of psychosis in adolescence.
At least one study has shown a decrease in depression in cannabis users.
A July 2006 study by Ellgren et al. strictly tested lab rats for the biological mechanism of the gateway drug effect. The study administered 6 "teenage" (28 and 49 days old) rats delta-9-tetrahydrocannabinol, and 6 were the control. One week after the first part was completed, catheters were inserted in the jugular vein of all of the adult rats and they were able to self-administer themselves heroin by pushing a lever. The study found that initially both groups behaved the same and began to self-administer heroin frequently, but then stabilized at different levels. The rats that had previously been administered THC consumed about 1.5 times more heroin than those that had not. Because many THC receptors interact with the opioid system, the study found that adolescent cannabis use overstimulates and alters the pleasure and reward structures of the brain, thus increasing the already high risk of addiction for people who start to use heroin. However, Other studies have shown that the dopamine system is independent of the THC receptor glands thus negating these negative effects. Psychopharmacologist Ian Stolerman, from King's College London, finds the biological cannabis gateway drug effect "somewhat preliminary", and states "it's too early to say there's a consensus, but a small number of studies like this suggest that there is a physiological basis for this effect." Other drugs, he notes, such as cocaine and amphetamines are involved in another brain pathway called the dopaminergic system. Cells in that system also interact with THC receptors and could be modified by cannabis exposure. Cannabinoid receptors are 10 times more prevalent in the brain than opioid receptors. According to Dr. Hurd, one of the study leaders, two other drugs that also stimulate opioid cells, and could therefore also feasibly cause a gateway effect, are nicotine and alcohol.
However, a December 2006 study by the American Psychiatric Association challenges these findings. A 12 year study on 214 boys from ages 10-12 showed that adolescents who used marijuana prior to using other drugs, including alcohol and tobacco, were no more likely to develop a substance abuse disorder than other subjects in the study. "This evidence supports what's known as the common liability model ... [which] states [that] the likelihood that someone will transition to the use of illegal drugs is determined not by the preceding use of a particular drug, but instead by the user's individual tendencies and environmental circumstances," investigators stated in a press release. They added, "The emphasis on the drugs themselves, rather than other, more important factors that shape a person's behavior, has been detrimental to drug policy and prevention programs."
Models used in a 2002 study by RAND cast doubt on the gateway effect and show "that the marijuana gateway effect is not the best explanation for the link between marijuana use and the use of harder drugs," as noted by Andrew Morral, associate director of RAND's Public Safety and Justice unit and lead author of the study.
Some studies conclude that there is a correlation of cannabis use and some symptoms of psychosis, but don't necessarily support the notion that cannabis use is a sufficient or necessary cause for psychosis. It might be a component cause, part of a complex constellation of factors leading to psychosis, or it might be a correlation without forward causality at all.
For example, a review of the evidence by Louise Arsenault, et al., in 2004 reports that on an individual level, cannabis use confers an overall twofold increase in the relative risk of later schizophrenia, assuming a causal relationship. This same research also states that "There is little dispute that cannabis intoxication can lead to acute transient psychotic episodes in some individuals". The study synthesizes the results of several studies into a statistical model. The study does not correct for the use of other illicit drugs, and relies on self-reporting of cannabis dosage. The study also does not determine if the cannabis use preceded or followed the mental health problem.
Similarly, a landmark study, in 1987, of 50,000 Swedish Army conscripts, found that those who admitted at age 18 to having taken cannabis on more than 50 occasions, were six times more likely to develop schizophrenia in the following 15 years. In fact, psychosis cases were restricted to patients requiring a hospital admission. These findings have not been replicated in another population based sample. As the study did not control for symptoms preexisting onset of cannabis use, the use of other illicit drugs, the study does not resolve the correlation versus causality question but has fueled a major debate within the scientific community. This study also used self reporting for cannabis dosage.
A 2005 study found that "the onset of schizotypal symptoms generally precedes the onset of cannabis use. The findings do not support a causal link between cannabis use and schizotypal traits". It should be noted that a schizotypal personality disorder is a personality disorder different from schizophrenia. A 2007 British study concluded, "We found few appreciable differences in symptomatology between schizophrenic patients who were or were not cannabis users. There were no differences in the proportion of people with a positive family history of schizophrenia between cannabis users and non-users. This argues against a distinct schizophrenia-like psychosis caused by cannabis.
Research based on the Dunedin Multidisciplinary Health and Development Study has found that those who begin regular use of cannabis in early adolescence (from age 15, median 25 days per year by age 18) and also fit a certain genetic profile (specifically, the Val/Val variant of the COMT gene) are five times more likely to develop psychotic illnesses than individuals with differing genotypes, or those who do not use cannabis. The study was noted for having controlled for preexisting symptoms, but is open to the criticism that it cannot control for late adolescent onset of psychotic illness. Also, the study was on a cohort population, so there is no way to correlate a change in the rate of adolescent use with a change in the rate of incidence of schizophrenia in the study population. These points undermine its value in resolving the correlation versus causality question.
A study that inversely correlated cerebrospinal anandamide (an endogenous cannabinoid) levels with severity of schizophrenia (i.e., that anandamide was released in order to suppress psychosis) suggests that cannabis use may be an effect of schizophrenia or its predisposition, as opposed to a cause.
The fact that the prevalence of cannabis use has increased substantially during the last decades whereas the prevalence of psychotic illness has not suggests no causal relationship.
A 2008 review of the evidence surrounding the acute impact on memory concluded that cannabinoids impair all aspects of short-term memory, especially short-term episodic and working memory. One small study found that no learning occurred during the 2 hour period in which the subjects were "stoned". Long-term effects on memory may be balanced by neuroprotective effects of THC against excitotoxicity. A 2008 study suggests that long-term, heavy cannabis use (>five joints daily for >ten years) are associated with structural abnormalities in the hippocampus and amygdala areas of the brain. The hippocampus, thought to regulate emotion and memory, and the amygdala, involved with fear and aggression, tended to be smaller in heavy and long term cannabis users than in controls (volume was reduced by an average of 12 percent in the hippocampus and 7.1 percent in the amygdala).
A 1998 Journal of Neuroscience in vitro research, which was carried out on hippocampal cells excised from decapitated rats, using THC carried in ethanol to saturate the neurons, suggests that THC is toxic for cultured hippocampal neurons.
A 1998 report by INSERM and CNRS, which was directed by Dr. Pierre-Bernard Roques, determined that, "former results suggesting anatomic changes in the brain of chronic cannabis users, measured by tomography, were not confirmed by the accurate modern neuro-imaging techniques (such as MRI) ... Moreover, morphological impairment of the hippocampus [which plays a part in memory and navigation] of rat after administration of very high doses of THC was not shown." He concluded that cannabis does not have any neurotoxicity as defined in the report, unlike alcohol and cocaine.
In many countries, experimental science regarding cannabis is legally restricted because cannabis is illegal. Thus, cannabis as a drug is often hard to fit into the structural confines of medical research because appropriate, research-grade samples are difficult to obtain legally for research purposes, unless granted under authority of national governments.
The cannabis that is available for research studies in the United States is grown at the University of Mississippi and solely controlled by the NIDA, which has veto power over the Food and Drug Administration (FDA) to define accepted protocols. Since 1942, when cannabis was removed from the U.S. Pharmacopoeia and its medical use was prohibited, there have been no legal (under federal law) privately funded cannabis production projects. This has resulted in a limited amount of research being done and possibly NIDA's producing cannabis which has been alleged to be of very low potency and inferior quality.
MAPS, in conjunction with Professor Lyle Craker, PhD, the director of the Medicinal Plant Program of the University of Massachusetts at Amherst, sought to provide independently grown cannabis of more appropriate research quality for FDA-approved research studies, and encountered opposition by NIDA, the ONDCP, and the U.S. Drug Enforcement Administration (DEA).
Tobacco smoking has well-established risks such as bronchitis, coughing, overproduction of mucus, wheezing and addiction. Similar risks for smoking cannabis related to airway inflammation have been suggested in a study of healthy cannabis users who exhibited similar early characteristics to tobacco smoking.
The effects of tobacco and cannabis smoking differ, however, as they affect different parts of the respiratory tract: whereas tobacco tends to penetrate to the smaller, peripheral passageways of the lungs, cannabis tends to concentrate on the larger, central passageways. One consequence of this is that cannabis, unlike tobacco, does not appear to cause emphysema, though this claim is disputed. A 2002 report by the British Lung Foundation estimated that three to four cannabis cigarettes a day were associated with the same amount of damage to the lungs as 20 or more tobacco cigarettes a day. Unlike tobacco, regular cannabis use does not appear to cause chronic obstructive pulmonary disease.
It is important to note that, in some cases, cannabis users mix commercial tobacco in joints, called "Spliff" (popular in Europe), tobacco mixed with hash in a chillum (India), or cannabis rolled in tobacco leaves (Blunt), which would expose the user to the additional risks of tobacco, such as rapid physical addiction to nicotine.
A previous study published in 2006 by Donald Tashkin of the University of California, Los Angeles had concluded there is no link between smoking cannabis and lung cancer.
A study published in 2006 on a large population sample (1,200 people with lung, neck, or head cancer, and a matching group of 1,040 without cancer) failed to positively correlate a lung cancer risk. The results indicated a slight negative correlation between long and short-term cannabis use and cancer, suggesting a possible therapeutic effect. Cellular studies and even some studies in animal models suggest that THC has antitumor properties, either by encouraging programmed cell death of genetically damaged cells that can become cancerous, or by restricting the development of the blood supply that feeds tumors.
Prior, a 1997 study examining the records of 64,855 Kaiser patients (14,033 of whom identified themselves as current smokers), also found no positive correlation between cannabis use and cancer.
A Research Triangle Institute study concluded that THC, a dilative agent, may help cleanse the lungs by dilating the bronchi, and could actively reduce the instance of tumors. Additionally, a study by Rosenblatt et al. found no association between marijuana use and the development of head and neck squamous cell carcinoma. However, a contrasting 2000 study linked the smoking of cannabis to the growth of cancerous tumors through the impairment of anti-tumor defenses.
The health consequences of cannabis use may vary depending on method of use. Proposed alternatives include:
Like tobacco smoke, cannabis smoke contains tars which are rich in carcinogenic polycyclic aromatic hydrocarbons, which are a prime culprit in smoking-related cancers. However, cannabinoids themselves are not carcinogenic. An obvious way to protect smokers' health is therefore to minimize the content of smoke tars relative to cannabinoids.
The most obvious way to do this is to bypass smoking completely by simply eating the cannabis by extracting the THC and other cannabinoids to a fat (like butter) or alcoholic drink, such as Green Dragon, or by vaporization.
Another way is to increase the THC potency of the cannabis (see also section on potency above). This can be done with hashish, honey oil, or high-quality cannabis. Assuming smokers adjust their smoke intake to the cannabinoid dosage by using a miniature utensil, the higher the concentration of cannabinoids, the lower the amount of tars—- and carbon monoxide—- they are likely to consume to achieve their desired effect.
Vaporizers, by heating the cannabis active constituents and aromatic substances to be inhaled without combustion of the preparation, almost exclude the risk altogether. A 2000 study conducted by NORML and MAPS found that the two tested vaporizers delivered significantly fewer carcinogens than a cigarette.
A lower temperature combustion method; like burning a cooler fuel, or focusing a magnifying glass in respect to the sun, are other ways to selectively burn substances without a vaporizer or water pipe.
The fungi Aspergillus flavus, Aspergillus fumigatus, Aspergillus niger, Aspergillus parasiticus, Aspergillus tamarii, Aspergillus sulphureus, Aspergillus repens, Mucor hiemalis (not a human pathogen), Penicillin chrysogenum, Penicillin italicum and Rhizopus nigrans have been found in moldy cannabis. Aspergillus mold species can infect the lungs via smoking or handling of infected cannabis and cause opportunistic and sometimes deadly Aspergillosis. Some of the microorganisms found create aflatoxins, which are toxic and carcinogenic. Researchers suggest that moldy cannabis thus be discarded.
Mold may also not be readily apparent. It is also found in smoke from mold infected cannabis, and the lungs and nasal passages are a major means of contracting fungal infections. "Levitz and Diamond (1991) suggested baking marijuana in home ovens at 150 °C [302 °F], for five minutes before smoking. Oven treatment killed conidia of A. fumigatus, A. flavus and A. niger, and did not degrade the active component of marijuana, tetrahydrocannabinol (THC)."
Shear strength and dilative characteristics of an unsaturated compacted completely decomposed granite soil.(Report)
Oct 01, 2010; Introduction Since the 1950s, several investigations have been carried out to help understand the principles of unsaturated soil...
Mechanisms Involved in the Differential Reduction of Omega-3 and Omega-6 Highly Unsaturated Fatty Acids by Structural Heart Disease Resulting in "HUFA Deficiency"
Jan 01, 2012; Introduction The identification of causes for the apparently mixed outcome of clinical trials on omega-3 highly unsaturated fatty...